Out-of Pocket Costs More Important Than Drug Rise
The Wall Street Journal, Steve Collis
While the article “Drug Prices Climb By 5.8%” (Page One, Jan. 3) points to the complexities behind pharmaceutical drug pricing, the real issue is rising patient out-of-pocket costs owing to insufficient benefit design.
When you compare individual cost sharing for hospital care versus outpatient medications, you can see the problem. Centers for Medicare & Medicaid Services data for 2018 show that U.S. spending on hospital care was more than $1 trillion compared with $335 billion for outpatient prescription drugs.
For the full op-ed from CEO Steve Collis, visit The Wall Street Journal.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.